Search articles by title, topic or section.
Khabre desk
Recent reporting, analysis and explainers from the Oncology desk.
health
A South Korean phase 1b/2 trial found a 55% objective response rate when trastuzumab and nivolumab were added to gemcitabine and cisplatin for previously untreated HER2-positive advanced biliary tract cancer. The single-arm results provide early evidence for first-line HER2-targeted chemoimmunotherapy, while randomized confirmation is still needed.
health
A Nature Medicine study developed EAGLE, an AI model that identifies esophageal cancer and precancerous lesions on noncontrast chest CT scans. It was validated across 80,612 patients in 12 centres and three countries, including routine and low-dose CT settings.
health
A methylation-based blood test detected recurrence of non-viral head and neck cancer with 76.9% sensitivity and 94.6% specificity, and preceded clinical detection by a median of 131 days in 60% of cases where both occurred. Positive results were strongly associated with worse one-year survival.
health
NHS England will make trastuzumab deruxtecan, sold as Enhertu, available to around 1,000 women with HER2-low advanced or metastatic breast cancer after their disease progresses following treatment.
health
A retrospective study of 2,396 people with advanced NSCLC found clinical-data AI models outperformed single biomarkers and helped physicians predict treatment response and survival.
health
In a randomized phase 2 trial, teclistamab produced deeper responses and longer progression-free survival than lenalidomide-dexamethasone in people with high-risk smoldering multiple myeloma. The study found high rates of complete response and minimal residual disease negativity after fixed-duration treatment.